PAT-DX1 / Patrys - LARVOL DELTA

Patrys Appoints Global Biotechnology Leader as Chairman - In Preparation for First Clinical Trial for Groundbreaking Cancer Therapy (Businesswire) - "Patrys Limited...announced the appointment of Dr. Charmaine Gittleson as the Chairman of the Board of Directors – a highly respected and experienced global biotechnology leader....Dr. Gittleson joins Patrys at an exciting time in the Company’s evolution as it completes the last remaining stages of preclinical development for its first-in-class anti-cancer antibody PAT-DX1, which is scheduled to commence first in human studies in the second half of 2023."

New trial • Oncology

"#Patrys reported #PATDX1 Engineering Run Update https://t.co/1pd377Dp1t" (@1stOncology)

"#Patrys reported that #PATDX1 Improves Survival in Animal Model of #BrainCancer https://t.co/CrYfkiqOOw" (@1stOncology)

Brain Cancer • Oncology • Solid Tumor

"#Patrys reported that #PATDX1 Engineering Run Successfully Completed https://t.co/ZDykUOkoza" (@1stOncology)

"#Patrys provided #PATDX1 Engineering Update https://t.co/zrB3V3Xw38" (@1stOncology)

"#Patrys reported #PATDX1 Significantly Improves Survival in Animal Model of #PancreaticCancer https://t.co/OCTBq5lelw" (@1stOncology)

Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

Patrys Limited Announces Publication of PAT-DX1 Preclinical Data in JCI – Insight (Businesswire) - “Patrys…announced the publication of preclinical data for its therapeutic antibody candidate PAT-DX1 in The Journal of Clinical Investigation—Insight. Patrys is developing PAT-DX1 for use in DDR-deficient cancers, including a range of primary brain cancers and metastases…Efficacy studies conducted in three mouse models of human cancer showed that PAT-DX1 is able to cross the BBB and suppress both orthotopic glioblastoma and metastatic triple negative breast cancer. The suppression of glioblastoma growth or brain metastasis resulted in statistically significant survival benefits…‘We are excited by the potential that PAT-DX1 shows in animal models of these cancers and are on track for the first-in-human study of our lead deoxymab asset, PAT-DX1, in mid 2022.”

New trial • Preclinical • Brain Cancer • Breast Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Triple Negative Breast Cancer